| Literature DB >> 20592748 |
Harald Hampel1, Richard Frank, Karl Broich, Stefan J Teipel, Russell G Katz, John Hardy, Karl Herholz, Arun L W Bokde, Frank Jessen, Yvonne C Hoessler, Wendy R Sanhai, Henrik Zetterberg, Janet Woodcock, Kaj Blennow.
Abstract
Advances in therapeutic strategies for Alzheimer's disease that lead to even small delays in onset and progression of the condition would significantly reduce the global burden of the disease. To effectively test compounds for Alzheimer's disease and bring therapy to individuals as early as possible there is an urgent need for collaboration between academic institutions, industry and regulatory organizations for the establishment of standards and networks for the identification and qualification of biological marker candidates. Biomarkers are needed to monitor drug safety, to identify individuals who are most likely to respond to specific treatments, to stratify presymptomatic patients and to quantify the benefits of treatments. Biomarkers that achieve these characteristics should enable objective business decisions in portfolio management and facilitate regulatory approval of new therapies.Entities:
Mesh：
Substances：
Year: 2010 PMID： 20592748 DOI： 10.1038/nrd3115
Source DB: PubMed Journal: Nat Rev Drug Discov ISSN： 1474-1776 Impact factor: 84.694